Clinical trials: in Czechia
Primary Membranous Nephropathy
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
- Trial name
- OLYMPUS (NCT07204275)
- Testing
- Povetacicept, Tacrolimus
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 176 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Metastatic Castration-Resistant Prostate Cancer
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
- Trial name
- NCT06629779
- Testing
- PF-06821497, Enzalutamide
- Where
- 231 sites in United States, Argentina and 25 more
- Volunteers
- 900 people
- Sponsor
- Pfizer
Atrial Arrhythmia, Atrial Fibrillation
VOLT CE Mark Study
This clinical investigation is intended to demonstrate safety and effectiveness of the Volt™ Pulsed Field Ablation (PFA) Catheter Sensor Enabled™, the Volt™ PFA Generator, Agilis™ NxT Steerable Introducer Dual-Reach™, and EnSite™…
- Conditions
- Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
- Trial name
- NCT06106594
- Testing
- Pulsed Field Ablation
- Where
- 11 sites in Australia, Austria and 5 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- Lenbelintide
- Where
- 220 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
- Trial name
- TILIA (NCT05624450)
- Testing
- Tozorakimab
- Where
- 473 sites in United States, Argentina and 37 more
- Volunteers
- 3,527 people
- Sponsor
- AstraZeneca
Prostate Cancer, Prostatic Neoplasms
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC.
- Trial name
- NCT06925737
- Testing
- Ifinatamab deruxtecan, Docetaxel, Prednisone
- Where
- 303 sites in United States, Argentina and 33 more
- Volunteers
- 1,440 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Neoplasms
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group.
- Trial name
- NCT07173751
- Testing
- Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine
- Where
- 224 sites in United States, Argentina and 17 more
- Volunteers
- 558 people
- Sponsor
- BioNTech SE
Schizophrenia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
- Trial name
- NCT07686263
- Testing
- Xanomeline/Trospium Chloride
- Where
- 54 sites in United States, Argentina and 5 more
- Volunteers
- 472 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Persistent Atrial Fibrillation, Pulsed-field Ablation
Pulsed-field Ablation in Patients With Persistent Atrial Fibrillation
Since a new method called pulsed-field ablation (PFA) has emerged, allowing significantly simpler, safer, and faster creation of ablative lesions in paroxysmal AF and PsAF (13), redefining the "optimal" ablation approach started…
- Trial name
- PIVCO (NCT05922917)
- Testing
- pulsed-field ablation
- Where
- 3 sites in Czechia
- Volunteers
- 518 people
- Sponsor
- České Budějovice Hospital
Malignant Neoplasm
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Researchers are looking for new ways to treat children with relapsed or refractory solid tumors: Relapsed means the cancer came back after treatment Refractory means the cancer did not respond (get smaller or go away) to…
- Trial name
- NCT07630974
- Testing
- Ifinatamab Deruxtecan
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Breast Cancer
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as…
- Trial name
- EvoPAR-BR01 (NCT06380751)
- Testing
- Saruparib (AZD5305), Camizestrant, Abemaciclib
- Where
- 306 sites in United States, Argentina and 27 more
- Volunteers
- 788 people
- Sponsor
- AstraZeneca
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are…
- Trial name
- NCT04613596
- Testing
- Adagrasib, Pembrolizumab
- Where
- 770 sites in United States, Argentina and 45 more
- Volunteers
- 626 people
- Sponsor
- Mirati Therapeutics Inc.
Graves' Disease
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid…
- Trial name
- NCT07018323
- Testing
- IMVT-1402
- Where
- 163 sites in United States, Australia and 16 more
- Volunteers
- 210 people
- Sponsor
- Immunovant Sciences GmbH
Schizophrenia; Psychosis, Cognitive Impairment
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Schizophrenia is a long-lasting and serious mental health disorder that affects about 1% of people worldwide. It can cause symptoms such as hallucinations and delusions (called positive symptoms), confused or disorganized…
- Trial name
- SHINE (NCT07084831)
- Testing
- Xanomeline/trospium
- Where
- 16 sites in Austria, Belgium and 8 more
- Sponsor
- European Group for Research In Schizophrenia
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
- Trial name
- ABLE-32 (NCT06510374)
- Testing
- Nadofaragene Firadenovec
- Where
- 116 sites in United States, Canada and 8 more
- Volunteers
- 454 people
- Sponsor
- Ferring Pharmaceuticals
Adenomyosis, Adenomyoma of Uterus
Ultrasound-Guided Radiofrequency Ablation for Focal Adenomyosis
This single-center, single-arm, open-label study evaluates the efficacy and safety of ultrasound-guided radiofrequency ablation (RFA) in women with symptomatic focal adenomyosis who wish to preserve the uterus.
- Trial name
- RFA-ADENO-USG (NCT07906535)
- Testing
- Myoblate Radiofrequency Ablation System (Mygen V-1000 generator)
- Where
- Czechia
- Volunteers
- 41 people
- Sponsor
- University Hospital Pilsen
Type 2 Diabetes Mellitus
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus…
- Trial name
- Eluminate-5 (NCT07662109)
- Testing
- Elecoglipron, Dapagliflozin
- Where
- 303 sites in United States, Argentina and 22 more
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Urinary Incontinence , Stress, Laser Therapy
Standardized 4D Transperineal Ultrasound Assessment of Urethrovesical Junction Mobility After Vaginal Laser Treatment for Stress Urinary Incontinence.
This prospective single-center observational cohort study will assess changes in urethrovesical junction (UVJ) mobility and urethral morphology after vaginal Er:YAG laser treatment in 40 adult women with pure stress urinary…
- Trial name
- NCT07907016
- Where
- Czechia
- Volunteers
- 40 people
- Sponsor
- Charles University, Czech Republic
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory…
- Trial name
- SUCCESSOR-1 (NCT05519085)
- Testing
- mezigdomide, Pomalidomide, Bortezomib
- Where
- 266 sites in United States, Argentina and 27 more
- Volunteers
- 810 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.